Seeking Alpha·Sep 15, 2026
Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptStevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Stevanato Group is in a major capacity expansion phase, with capital expenditure averaging 28.8% of revenue over the last ten quarters, which has suppressed free cash flow and liquidity. While the company demonstrated strong operating leverage with a 19.2% ope...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 4, 2026 | $0.16+10.5% vs $0.14 | $345M+1.3% vs $341M |
Q2 2026 May 7, 2026 | $0.13+8.3% vs $0.12 | $316M+1.8% vs $310M |
Q2 2026 Mar 4, 2026 | $0.21+5.0% vs $0.20 | $407M+4.0% vs $391M |
Q4 2025 Nov 6, 2025 | $0.16+14.3% vs $0.14 | $355M-7.9% vs $385M |
Stevanato Group S.p.A. (STVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: Tuesday, September 15, at 1:50 p.m. (ET) – Morgan Stanley Annual Global Healthcare Conference, New York, NY Tuesday, September 22, at 8:25 – 9:05 a.m. (GMT) – BofA Global Healthcare Confere.
On September 01, 2026, Stevanato Group SpA (STVN) shares fell 3.4% to a current price of $20.71, trading within a 52-week range of $12.89 to $28.00. This recent
Stevanato Group is transforming from a pharmaceutical glass supplier into an integrated drug containment and delivery platform, validated by commercial adoption of its Alina injector. High-value solutions now drive 45% of revenue, growing 16% year-over-year, with recent capacity investments in Fishers and Latina expected to boost operating leverage and margin expansion. STVN is shifting its portfolio toward premium, integrated offerings, divesting low-margin assets like Balda and focusing on durable, higher-margin customer relationships.
Benchmark STVN against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Stevanato Group S.p.A. (STVN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $21.69 | $5.92B | 38.88 | 3.21% | 11.78% | 9.29% | 0.27% | |
| $36.78 | $767.54M | 14.60 | 3.21% | 4.88% | 13.43% | — | |
| $168.24 | $5.41B | 35.42 | 8.75% | 15.14% | 12.79% | — | |
| $182.52 | $50.29B | 31.31 | 8.23% | 4.52% | 3.79% | — | |
| $375.97 | $26.46B | 55.29 | 6.26% | 16.98% | 18.51% | — | |
| $209.90 | $10.05B | 636.06 | 2.49% | -0.63% | -0.78% | — |
Stevanato Group S.p.A. (STVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when STVN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Stevanato Group S.p.A. (STVN) stock FAQ — growth, dividends, profitability & financials explained
Stevanato Group S.p.A. (STVN) reported $1.22B in revenue for fiscal year 2025. This represents a 128% increase from $536.5M in 2019.
Stevanato Group S.p.A. (STVN) grew revenue by 3.2% over the past year. Growth has been modest.
Yes, Stevanato Group S.p.A. (STVN) is profitable, generating $134.2M in net income for fiscal year 2025 (11.8% net margin).
Yes, Stevanato Group S.p.A. (STVN) pays a dividend with a yield of 0.27%. This makes it attractive for income-focused investors.
Stevanato Group S.p.A. (STVN) has a return on equity (ROE) of 9.3%. This is below average, suggesting room for improvement.
Stevanato Group S.p.A. (STVN) had negative free cash flow of $25.6M in fiscal year 2025, likely due to heavy capital investments.
